Aclaris Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:ACRS) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 220.33 M198.09 M189.15 M175.53 M160.46 M198.72 M Total liabilities 64.77 M54.03 M57.41 M55.43 M57.38 M55.07 M Total equity 155.55 M144.07 M131.74 M120.1 M103.08 M143.65 M Total liabilities & shareholders' equities 220.33 M198.09 M189.15 M175.53 M160.46 M198.72 M Total debt —————— Net debt ——————

News

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - Slideshow (NASDAQ:ACRS) 2026-04-28

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Aclaris starts phase 1b trial of ATI-052 in asthma patients

Craig-Hallum initiates coverage on Aclaris Therapeutics stock with Buy rating